<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33593">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02082119</url>
  </required_header>
  <id_info>
    <org_study_id>1138</org_study_id>
    <nct_id>NCT02082119</nct_id>
  </id_info>
  <brief_title>Hypofractionated IMRT With Temozolomide for HGG</brief_title>
  <official_title>Hypofractionated IMRT (VMAT-RA) With Temozolomide for Patients With Newly Diagnosed High Grade Glioma (HGG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <authority>Italy: National Bioethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and feasibility  of  hypofractionated IMRT in addition to chemotherapy,
      concomitant and adjuvant,  in patients with newly diagnosed  HGGs after surgery.

      Primary endpoint:  progression free survival (PFS),  Overall Survival (OS)  and Toxicity.

      Secondary endpoint: to evaluate Quality of life (QoL)  of patients after surgery,
      concomitant chemoradiotherapy and adjuvant chemotherapy through neuropsychological
      examination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed a study of a hypofractionated intensity modulated radiation therapy (IMRT),
      using VMAT RapidArc approach. The potential advantage of this approach is to deliver a more
      selective irradiation to tumor's target with reducing dose to normal brain and to allow to
      deliver a higher dose, optimizing the therapeutic window
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival (PFS),  Overall Survival (OS)  and Toxicity</measure>
    <time_frame>time of enrollment of two years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)  of patients after surgery, concomitant chemo-radiotherapy and adjuvant chemotherapy</measure>
    <time_frame>two years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>High Grade Glioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant,  in patients with newly diagnosed  High Grade Glioma after biopsy.total dose of 60 Gy/ 4 Gy fraction/15 fractions (BED10 84 Gy)  will prescribed to the PTV1; a total dose of  42 Gy/2.8 Gy fraction/15 fractions (BED10 53.76 Gy) will prescribed to PTV2  with SIB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated IMRT</intervention_name>
    <description>Hypofractionated IMRT</description>
    <arm_group_label>High Grade Glioma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 70 years

          -  Karnosky performance status (KPS) ≥60

          -  Patients aged &gt;70 years with KPS ≥80

          -  Histopathologically confirmed of HGG

          -  Estimated survival  ≥ 3 months.

          -  Multifocal tumor

          -  Normal liver, Kidney and bone marrow function

          -  Written informed consent

        Exclusion Criteria:

          -  Prior radiation therapy

          -  KPS ≤ 60

          -  Age &gt; 70 years and KPS &lt; 70

          -  Other primary cancer

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piera Navarria, MD</last_name>
    <role>Study Director</role>
    <affiliation>Humanitas Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Milan</city>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piera Navarria, MD</last_name>
      <phone>+39-02-8224-7458</phone>
      <email>piera.navarria@humanitas.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):655-60. doi: 10.1016/j.ijrobp.2012.01.035. Epub 2012 Apr 5.</citation>
    <PMID>22483738</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>December 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>Istituto Clinico Humanitas</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
